Iovance Biotherapeutics, Inc. IOVA
As ofNov 19, 2026, 2:15 PM EST
- YTD
- +169.41%
- 1 year
- +225.44%
5D -0.25 (-3.28%)
- Market cap
- 3.41B
- Revenue (ttm)
- 378.98M
- Profit margin
- -58.19%
- EPS (ttm)
- -0.49
- Shares out
- 462.66M
- Forward P/E
- -65.68
- YTD return
- +169.41%
- 1-year return
- +225.44%
- 50-day average
- 11.29
- 200-day average
- 6.16
- Volume
- 4.48M
- Avg volume
- 15.68M
- Open
- 7.54
- Previous close
- 7.48
- Day's range
- 7.34 – 7.70
- 52-week range
- 2.08 – 15.37
- Beta
- 0.84
- Analysts
- Buy
- Price target
- 14.50 (+97.1%)
- Earnings date
- Feb 23, 2027
Key statistics
- Enterprise value
- 3.15B
- Price / sales
- 9.13
- Price / book
- 4.26
- Revenue growth
- 80.10%
- Free cash flow
- -139.86M
- Total cash
- 376.32M
- Total debt
- 45.21M
- Return on equity
- -29.12%
- Short % of float
- 15.05%
Fundamental scorecard
7 of 25 checks passed on IOVA’s reported financials
7of 25 checks passed
- Value 1 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 8.00
- Target (mean)
- 14.50
- Target (high)
- 20.00
- Strong buy2
- Buy5
- Hold2
- Sell0
- Strong sell0
Next earnings
Feb 23, 2027
Expected Feb 23, 2027. Consensus EPS estimate -0.04438.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 23, 2027 | Dec 30, 2026 | -0.07 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | -0.08409 | -0.05 | +0.03 | +40.54% |
| Aug 6, 2026 | Jun 30, 2026 | -0.13346 | -0.11 | +0.02 | +17.58% |
| May 7, 2026 | Mar 31, 2026 | -0.19 | -0.19 | 0.00 | 0.00% |
| Feb 24, 2026 | Dec 31, 2025 | -0.22 | -0.18 | +0.04 | +18.18% |
| Nov 6, 2025 | Sep 30, 2025 | -0.29 | -0.25 | +0.04 | +13.79% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | Barclays | main | Overweight | Overweight |
| Nov 6, 2026 | Citizens | main | Market Outperform | Market Outperform |
| Nov 3, 2026 | UBS | main | Neutral | Neutral |
| Oct 13, 2026 | Barclays | main | Overweight | Overweight |
| Oct 8, 2026 | Baird | main | Neutral | Neutral |
| Sep 30, 2026 | Wells Fargo | main | Overweight | Overweight |
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in Philadelphia, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- iovance.com
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
Iovance Biotherapeutics Targets 2027 Lung Cancer Filing as AMTAGVI Sales Climb
Iovance: The Lung Selloff Went Too Far For A Business Growing 77%
Iovance Biotherapeutics to Present at Upcoming Conference
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $19
Citizens Maintains Market Outperform on Iovance Biotherapeutics, Raises Price Target to $12
Iovance Biotherapeutics Q3 2026 Earnings Call Transcript Iovance Biotherapeutics Affirms FY2026 Sales Guidance of $410.000M-$420.000M vs $416.263M Est
Iovance Biotherapeutics Q3 EPS $(0.05) Beats $(0.09) Estimate, Sales $121.469M Beat $115.982M Estimate
Your note
Sign in to keep a note on IOVA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BELLEMIN JEAN-MARC | Chief Financial Officer | Conversion of Exercise of derivative security | Jun 1, 2025 | 60,529 |
| BILINSKY IGOR P | Chief Operating Officer | Conversion of Exercise of derivative security | Sep 7, 2026 | 142,074 |
| GRAF FINCKENSTEIN FRIEDRICH | Officer | Conversion of Exercise of derivative security | Jun 4, 2026 | 140,111 |
| KIRBY DANIEL GORDON | Officer | Conversion of Exercise of derivative security | Aug 9, 2026 | 154,511 |
| PURI RAJ K | Officer | Conversion of Exercise of derivative security | Sep 7, 2026 | 256,364 |
| ROCHE CORLEEN M | Chief Financial Officer | Conversion of Exercise of derivative security | Nov 5, 2026 | 35,946 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.19% | 37,903,960 | 283.52M | Sep 29, 2026 |
| MHR Fund Management, LLC | 6.26% | 28,967,103 | 216.67M | Sep 29, 2026 |
| State Street Corporation | 4.69% | 21,695,003 | 162.28M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 3.98% | 18,396,706 | 137.61M | Sep 29, 2026 |
| Two Sigma Investments, LP | 3.23% | 14,964,996 | 111.94M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 2.65% | 12,279,882 | 91.85M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.91% | 13,485,679 | 100.87M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.43% | 11,251,093 | 84.16M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.22% | 10,291,732 | 76.98M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.05% | 4,858,231 | 36.34M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.94% | 4,357,351 | 32.59M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.93% | 4,305,078 | 32.20M | Jun 29, 2026 |
